摘要
大量研究表明,在生理条件下,血浆中血管性血友病因子(von Willebrand factor,VWF)主要受金属蛋白酶,即血管性血友病因子裂解酶(von Willebrand factor—cleaving protease,VWF-cp)的调节,VWF—cp活性异常致血浆中超大VwF多聚体(UL.VwF)无法降解并蓄积,是导致血栓性血小板减少性紫癜(thrombotic thrombocytopenic purpura,TTP)发病的重要机制。
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2008年第6期704-707,共4页
Chinese Journal of Laboratory Medicine
参考文献37
-
1Fujikawa K, Suzuki H, McMullen B, et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood, 2001, 98: 1662-1666.
-
2Gerritsen HE, Robles R, Lammle B, et al. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood, 2001, 98:1654-1661.
-
3Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem, 2001, 130:475-480.
-
4Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metallopwtease involved in thrombotic thrombocytopenic purpura. J Biol Chem, 2001,276:41059-41063.
-
5Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 2001, 413:488-494.
-
6Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A, 2002, 99:11902-11907.
-
7Majerus EM, Zheng X, Tuley EA, et al. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem, 2003, 278:46643-46648.
-
8Shang D, Zheng XW, Niiya M, et al. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood, 2006, 108:2207-2215.
-
9Zheng X, Nishio K, Majerus EM, et al. Cleavage of yon Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem, 2003, 278:30136-30141.
-
10Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for yon Willebrand factor cleavage. Blood, 2003, 102:3232-3237.
同被引文献14
-
1王学文.血栓性血小板减少性紫癜患者血浆VW因子裂解蛋白酶活性测定的临床意义[J].医学研究生学报,2005,18(3):250-254. 被引量:3
-
2李世军,陈惠萍.血栓性微血管病的分类及发病机制[J].肾脏病与透析肾移植杂志,2006,15(6):546-551. 被引量:2
-
3韩红,邹萍.血栓性血小板减少性紫癜及其研究进展[J].临床内科杂志,2007,24(2):142-144. 被引量:22
-
4Moskowitz NP,Fligman I,Scimeea P,et al.Transient TTP in Childhood[J].Pediatr Blood Cancer,2009,52(3):424-426.
-
5Rock GA,Shurnak KH,Buskard NA,et al.Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura Canadian Aphcresis Study Group[J].N Engl J Meal,1991,325(6):393-397.
-
6Sarode R.Atypical Presentations of Thrombotic Thrombocytopenic Purpura:A Review[J].Journal of Clinical Apheresis,2009,24(1):47-52.
-
7Tao Z,Anthony K,Peng Y,et al.Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura[J].J Thromb Hacmost,2006,4(9):1931-1935.
-
8Shibagaki Y,Toshiro F.Thrombotic Microangiopathy in Malignant Hypertension and Hemolytic Uremic Syndrome(HUS)/Thrombotic Thrombocytopenic Purpura(TTP):Can We Differentiate One from the Other?[J].Hypertens Res,2005,28(1):89-95.
-
9Caramello V,Dovio A,Caraci P,et al.Thrombotic thrombocytopenic purpttra in advanced prostate cancer:Case report and published work review[J].International Journal of Urology,2007,14(2):150-152.
-
10Rock GA,Shumak KH,Buskard NA,et al.Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.Canadian Apheresis Study Group[J].N Engl J Med,1991,325(6):393-397.
二级引证文献3
-
1许敏,邓东红,杨杰,程鹏.血栓性血小板减少性紫癜18例临床分析[J].中国临床新医学,2013,6(5):425-428. 被引量:1
-
2刘小勇,覃凤娴.血栓性血小板减少性紫癜的诊疗新进展[J].医疗装备,2020,33(1):199-201. 被引量:3
-
3艾奇,乔丽津.血栓性微血管病的诊疗新进展[J].海南医学,2016,27(5):779-781. 被引量:7
-
1刘丹,汪涯雅,李海明,郑润辉,王春燕,黄振倩,谭获.低剂量利妥昔单抗治疗难治性血栓性血小板减少性紫癜2例并文献复习[J].临床血液学杂志,2014,27(3):418-421. 被引量:4
-
2沈蕾(综述),董宁征(审校),阮长耿(审校).ADAMTS13与炎症反应[J].国际输血及血液学杂志,2010(1):45-48.
-
3孟新.vWF-CP水平及GRACE评分评估冠心病患者危险分层的价值[J].中国老年学杂志,2015,35(22):6430-6431. 被引量:1
-
4毛建平,姜振宇,李薇,吴天姊,夏珊珊,吴婕.血栓性血小板减少性紫癜的发病机制及治疗进展[J].深圳中西医结合杂志,2006,16(6):390-394. 被引量:2
-
5高维强,周晓俊,白霞,苏健,阮长耿.原发性肝癌血管性血友病因子裂解酶的表达水平及意义[J].中华肝脏病杂志,2005,13(10):795-796. 被引量:3
-
6刘明,王智彬,许江虹.房颤患者vWF与ADAMTS-13水平的变化及意义[J].临床医学,2013,33(10):10-11. 被引量:3
-
7苏健,白霞,刘芳,高维强,余自强,王兆钺,阮长耿.血管性血友病因子裂解酶功能检测在血栓性血小板减少性紫癜诊断中的意义[J].中华检验医学杂志,2006,29(5):414-416. 被引量:1
-
8马志诚,詹丽.血管性血友病因子裂解酶与慢性阻塞性肺疾病患者炎性反应及血栓前状态的相关性分析[J].中国医师进修杂志,2016,39(10):941-943. 被引量:4
-
9陈劲松,匡希斌.急性冠脉综合征与血管性血友病因子裂解酶的关系[J].中国心血管病研究,2007,5(9):662-664. 被引量:3
-
10赵星,陈化.血管性血友病因子裂解酶(ADAMTS-13)研究进展[J].血栓与止血学,2009,15(4):186-188. 被引量:5